SICPA
SICPA, in collaboration with the International Air Transport Association (IATA) and other industry partners, supported the first travel experience using digital identity, streamlining the process from booking a flight to border crossing at arrival. The demonstration successfully took place on a journey from London Heathrow to Rome Fiumicino with British Airways and was presented at the IATA World Passenger Symposium in Chicago on 25 October 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231027663357/en/
(Photo: Business Wire)
The London to Rome journey serves as a proof of concept (PoC) of a project incubated in the IATA Innovation Lab since 2022, where SICPA provided its innovative technology for the creation and issuance of verifiable credentials (any document, object, or data that proves the identity of a person) through its digital identity platform, as part of a wider IATA project called “Identity Management in Distribution”. Other PoC industry partners include Accenture, Amadeus, Australian Border Force, AWS, Branchspace, British Airways, IDnow, Aeroporti di Roma, Trip.com and Verchaska.
“This strategic collaboration shows our strong dedication for innovation, and for pushing the boundaries of what is possible in the aviation and travel industry. It underpins our commitment to a future travel experience that is digital, efficient, biometrically secured, and leverages a digital identity approach. With this project, SICPA can further strengthen its commitment to digital identity protection, while respecting the rights of every citizen and in particular the protection of confidential data and privacy,” said Catherine Fankhauser, Head of Market Segment – Identity at SICPA.
"Thank you to SICPA for their collaboration in demonstrating the first fully integrated digital identity travel experience, from shopping for flights to arrival. Our goal has always been a future of travel that's fully digital and secured with biometric identification. Though we've had the technology for individual steps, bringing them together has been a challenge. Today, with the support of our partners, we've shown it's achievable. This is a significant stride towards simpler and smoother travel experiences in the future,” said Nick Careen, IATA’s Senior Vice President for Operations, Safety and Security.
Key highlights of the digital travel experience and PoC include:
Creation of a Portable Digital Identity: Digital identity “portability” gives people a way to create a single set of digital credentials - any document, object, or data (e.g., membership, etc) that proves the identity of a person - in a “Digital Identity Wallet”, which is required for travel.
Passengers can create a secure digital passport version in a few simple steps: scanning their passport with a mobile device and verifying identity through a biometric liveness check to guarantee that the holder is a human being, ensuring the link between the ID document with the rightful owner. The tamper-proof digital credential is stored in the digital wallet of the travellers and can be provided to third-party verifiers to have access to different types of services (e.g., flight booking, boarding, etc…). For privacy purposes, travellers can opt for selective disclosure, revealing only specific digital passport attributes as needed. Therefore, passengers have a full control on their personal data.
Other applications stemming from digital identity in travel: personalised offers (i.e., loyalty card and offers), simplified booking (streamlined e-ticket generation and journey detail), seamless travel requirements verification (pre-journey processes to confirm travel requirements), and simplified check-ins (enhancing the check-in process by sharing necessary digital documents with the airline), ensuring a full contactless airport experience. See IATA’s video
About IATA-SICPA partnership
Late 2022, SICPA was selected by IATA to provide its innovative digital identity technology as part of IATA’s “Identity Management in Distribution” project. The aim of this project is to establish an industry-wide approach to identifying and authenticating all parties in the airline distribution chain, including both accredited and non-accredited agents of airlines and other entities. The project was successfully put in production on 8 September 2023 with SICPA's digital identity platform as a critical component of the solution and is still running today. The 25 October proof of concept presented in Chicago constitutes a first milestone.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231027663357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom